Stomach Cancer Market Report 2026

The stomach cancer market size has grown rapidly in recent years. It will grow from $3.74 billion in 2025 to $4.26 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to rising incidence of gastric cancer globally, prevalence of helicobacter pylori infections, increasing use of chemotherapy as standard treatment, expansion of hospital oncology infrastructure, improvements in diagnostic imaging techniques.

The stomach cancer market size is expected to see rapid growth in the next few years. It will grow to $7.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to growing adoption of precision oncology, rising investment in novel biologics, expansion of immunotherapy pipelines, increasing focus on early-stage cancer detection, improving access to advanced cancer treatments. Major trends in the forecast period include increasing adoption of targeted therapy regimens, rising use of immunotherapy combinations, growing focus on early diagnostic screening, expansion of personalized treatment approaches, enhanced integration of biomarker-based testing.

The rising prevalence of Helicobacter pylori infection is expected to drive the growth of the stomach cancer market going forward. Helicobacter pylori infection is caused by the bacterium Helicobacter pylori, which colonizes the stomach lining and can result in inflammation, ulcers, and an elevated risk of stomach cancer. The increasing prevalence of Helicobacter pylori infection is mainly attributed to poor sanitation, which promotes fecal-oral and oral-oral transmission of the bacteria in overcrowded or unhygienic living environments. Helicobacter pylori infection contributes to stomach cancer by inducing chronic inflammation and cellular damage in the stomach lining, leading to precancerous lesions and tumor formation. For instance, in November 2024, according to the Government of Canada, a Canada-based government agency, the recurrence rate of Helicobacter pylori infection was 19% in 2023, with variations based on geographic location and age group. Therefore, the rising prevalence of Helicobacter pylori infection is fueling the growth of the stomach cancer market.

Major companies operating in the stomach cancer treatment market are focusing on developing advanced therapies such as claudin (CLDN18.2)-targeted cytolytic antibody therapy to improve precision in first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. Claudin (CLDN18.2)-targeted cytolytic antibody therapy involves a monoclonal antibody that selectively binds to CLDN18.2-expressing tumor cells and induces cytotoxic effects when used with chemotherapy, enhancing both progression-free and overall survival outcomes. For example, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical company, launched Vyloy (zolbetuximab-clzb), a CLDN18.2-directed cytolytic antibody for treating gastric and GEJ cancer. This innovative biologic therapy is administered intravenously alongside fluoropyrimidine- and platinum-based chemotherapy, providing a median progression-free survival of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. The therapy selectively targets CLDN18.2-positive cancer cells, reduces off-target toxicity, and increases treatment specificity, representing a significant advancement in personalized oncology for advanced gastric cancer.

In February 2025, GSK plc., a UK-based pharmaceutical company, acquired IDRx, Inc., for $1.15 billion. Through this acquisition, GSK aims to strengthen its oncology pipeline by advancing innovative targeted therapies for cancer treatment. IDRx, Inc. is a US-based biopharmaceutical company specializing in the discovery and development of precision oncology therapies that target specific genetic mutations in cancer.

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.

North America was the largest region in the stomach cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stomach cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the stomach cancer market by increasing costs of imported active pharmaceutical ingredients, biologics, diagnostic reagents, and specialized medical devices used in chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical manufacturing and hospital procurement in North America and Europe are most affected due to reliance on cross-border drug supply chains, while Asia-Pacific faces pricing pressure on oncology drug exports. These tariffs are increasing treatment costs and affecting affordability in some regions. However, they are also encouraging local drug manufacturing, regional clinical research investments, and domestic production of oncology therapeutics, supporting long-term market resilience.

The stomach cancer market research report is one of a series of new reports that provides stomach cancer market statistics, including stomach cancer industry global market size, regional shares, competitors with a stomach cancer market share, detailed stomach cancer market segments, market trends and opportunities, and any further data you may need to thrive in the stomach cancer industry. This stomach cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stomach cancer, also known as gastric cancer, is a disease in which malignant cells form in the lining of the stomach. It begins in the mucus-producing cells of the stomach’s inner layer and can spread to deeper layers and other parts of the body. Stomach cancer often develops slowly and may not show symptoms in its early stages, but as it progresses, symptoms such as stomach pain, nausea, weight loss, and loss of appetite may appear.

The primary types of stomach cancer are adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and other types. Adenocarcinoma is a cancer that forms in the glandular cells lining certain internal organs, commonly affecting the stomach, lungs, prostate, and colon. Treatments include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, administered via oral and parenteral routes. These therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, specialty clinics, ambulatory surgery centers, and others.

The stomach cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgical services, post-treatment monitoring and palliative care, genetic and biomarker testing, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stomach cancer market also includes sales of diagnostic tools and kits, surgical instruments and devices, companion diagnostics, supportive care medications, and biomarker testing kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.